Balaji Amines Ltd
Balaji Amines Ltd Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Expecting a minimum 15% growth in values and volumes in the next financial year as new plants commission and run at optimum capacity (Page 7). Company expects at least 15% growth in volume and value in the next financial year, driven by commissioning of new plants and expansions (Page 7).
From Balaji Amines Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Expecting a minimum 15% growth in values and volumes in the next financial year as new plants commission and run at optimum capacity (Page 7).
- Anticipate 7%-8% domestic market consumption growth for acetonitrile driven by cost-effective, user-friendly product demand in pharma (Page 9).
- Specialty Chemicals subsidiary revenue expected to remain similar to H1 FY '26 (~INR70 crores), with improvements post completion of brownfield modifications (Page 9).
- Volume growth of 8%-10% expected in the second half of FY '26 as approvals and market demand revive (Page 5).
- Gradual traction expected in the second half of FY '26 as new capacities commission and demand strengthens (Page 4).
- Exports expected to improve once brownfield capacity of 60 tons/day commences (Page 11).
- Overall positive medium-to-long-term outlook supported by product diversification, process innovation, and import substitution (Page 4).
Profitability & Margins
See what Balaji Amines Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Balaji Specialty Chemicals Limited is executing a INR750 crores expansion plan with mega project status under Maharashtra's Package Scheme of Incentives 2019.
- Unit 1 brownfield expansion for EDA-based products expected commissioning by September 2026.
- Unit 2 greenfield project at Chincholi progressing with equipment installation; commissioning expected by December 2026.
- New plants like DME (dimethyl ether) and N-methylmorpholine are under commissioning, expected by end of FY 2025-26.
- Acetonitrile plant expansion with improved technology slated for commissioning in FY 2026-27.
- All ongoing projects are being funded through internal accruals; company maintains zero debt and good cash position.
- Focus on product diversification, process innovation, and green chemistry initiatives to strengthen long-term growth.
- Expecting around 15% growth in volumes and values once new plants run at optimum capacity.
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Balaji Amines Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The transcript does not provide explicit details on the current or expected order book or pending orders for Balaji Amines Limited.
- However, the company mentions ongoing contracts and export orders, especially in the U.S. and Europe, with continuation and renewal signals for the coming financial year.
- Exports are currently limited due to capacity constraints and brownfield modifications but expected to pick up post-expansion.
- Domestic demand is stable with gradual recovery noted in pharma and agrochemical segments.
- Upcoming projects and expansions (e.g., Unit 1 brownfield and Unit 2 greenfield) are expected to enhance capacity and drive new orders.
- The company expects a 15% growth in volumes and values next financial year from commissioning new plants and increased capacity utilization.
- New products aligned with import substitution and specialty chemicals are anticipated to attract further orders in medium to long term.
Balaji Amines Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹395 Cr, net profit ₹65 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Balaji Amines Ltd's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Indian Phosphate Ltd (Q2 FY26)
H1 FY 25-26 revenue increased by ~15% to ₹451 crores versus ₹385 crores in H1 FY 24-25. Key concall takeaways from Indian Phosphate's Q2 FY26 earnings call…
- Alkyl Amines Chemicals Ltd (Q2 FY26)
120 crores. Key concall takeaways from Alkyl Amines Chemicals Ltd's Q2 FY26 earnings call — and how it ranks against sector peers.
- Sudarshan Chemical Industries Ltd (Q2 FY26)
The company completed a significant capex investment of roughly INR 700 crores about 3-4 years ago. Key concall takeaways from Sudarshan Chemical Industries…
- Gujarat Narmada Valley Fertilizers & Chemicals Ltd (Q2 FY26)
Capex pipeline worth INR 2,800 crores includes expansions in AN melt, weak nitric acid, power and steam plant conversion, and ammonia loop expansion. Key…
Frequently Asked Questions
What were Balaji Amines Ltd Q2 FY26 results?
Expecting a minimum 15% growth in values and volumes in the next financial year as new plants commission and run at optimum capacity (Page 7). Company expects at least 15% growth in volume and value in the next financial year, driven by commissioning of new plants and expansions (Page 7).
What is Balaji Amines Ltd share price analysis?
Balaji Amines Ltd currently shows a neutral. The stock trades at a P/E of 33.9 with a market cap of ₹6,914 Cr. Investors should review the full earnings analysis for detailed insights.
Is Balaji Amines Ltd planning capital expenditure?
Balaji Specialty Chemicals Limited is executing a INR750 crores expansion plan with mega project status under Maharashtra's Package Scheme of Incentives 2019.
Keep Balaji Amines Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.